GLS and cholangiocarcinoma: Our research aimed to validate novel LUAD-specific and GAC-specific methylation biomarkers that successfully differentiate LUAD and GAC from cholangiocarcinoma (CCA), colorectal carcinoma (CRC), hepatocellular carcinoma (HCC), pancreatic adenocarcinoma (PDAC) and the normal adjacent tissues (NATs).